Symbols / IONS Stock $71.78 -0.62% Ionis Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
IONS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Brett P. Monia Ph.D.
Exch · Country NMS · United States
Market Cap 11.85B
Enterprise Value 11.79B
Income -381.39M
Sales 943.71M
FCF (ttm) -154.72M
Book/sh 3.00
Cash/sh 16.23
Employees 1,402
Insider 10d —
IPO May 17, 1991
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -115.98
PEG 27.33
P/S 12.56
P/B 23.97
P/C —
EV/EBITDA -31.94
EV/Sales 12.50
Quick Ratio 3.51
Current Ratio 3.83
Debt/Eq 534.84
LT Debt/Eq —
EPS (ttm) -2.38
EPS next Y -0.62
EPS Growth —
Revenue Growth -10.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-29
Earnings (prior) 2026-02-25
ROA -7.31%
ROE -70.80%
ROIC —
Gross Margin 1.29%
Oper. Margin -105.47%
Profit Margin -40.41%
Shs Outstand 165.10M
Shs Float 163.91M
Insider Own 0.66%
Instit Own 106.05%
Short Float 10.99%
Short Ratio 6.89
Short Interest 13.76M
52W High 86.74
vs 52W High -17.25%
52W Low 29.85
vs 52W Low 140.47%
Beta 0.40
Impl. Vol. 0.78%
Rel Volume 1.12
Avg Volume 2.11M
Volume 2.37M
Target (mean) $98.74
Tgt Median $104.00
Tgt Low $47.00
Tgt High $130.00
# Analysts 23
Recom Buy
Prev Close $72.23
Price $71.78
Change -0.62%
About

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$98.74
Mean price target
2. Current target
$71.78
Latest analyst target
3. DCF / Fair value
$-16.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$71.78
Low
$47.00
High
$130.00
Mean
$98.74

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-23 main TD Cowen Buy → Buy $108
2026-04-21 init Canaccord Genuity — → Buy $110
2026-04-21 main Morgan Stanley Overweight → Overweight $130
2026-04-09 main B of A Securities Buy → Buy $111
2026-03-26 main Barclays Overweight → Overweight $106
2026-03-25 main Needham Buy → Buy $105
2026-03-25 main HC Wainwright & Co. Buy → Buy $120
2026-03-03 main Leerink Partners Outperform → Outperform $104
2026-02-27 main Piper Sandler Overweight → Overweight $100
2026-02-26 main Stifel Hold → Hold $77
2026-02-26 main Needham Buy → Buy $103
2026-02-06 main Piper Sandler Overweight → Overweight $87
2026-01-05 main Wells Fargo Overweight → Overweight $100
2025-12-17 main RBC Capital Outperform → Outperform $95
2025-12-15 main Leerink Partners Outperform → Outperform $100
2025-12-09 main B of A Securities Buy → Buy $97
2025-11-10 main HC Wainwright & Co. Buy → Buy $110
2025-11-04 main Piper Sandler Overweight → Overweight $77
2025-10-30 main TD Cowen Buy → Buy $99
2025-10-30 main Morgan Stanley Overweight → Overweight $94
News
RSS: Latest IONS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-16 BAROLDI JOSEPH Officer — 5,619 $74.56 $418,953
2026-04-16 BIRCHLER BRIAN Officer — 973 $75.04 $73,016
2026-04-16 JENNE KYLE Officer — 4,902 $75.17 $368,488
2026-04-15 BAROLDI JOSEPH Officer — 10,837 — —
2026-04-15 BIRCHLER BRIAN Officer — 1,875 — —
2026-04-15 JENNE KYLE Officer — 12,226 — —
2026-04-15 PARSHALL B LYNNE Director — 5,000 $76.19 $381,367
2026-04-02 DEVERS SHANNON L Officer — 6,193 $74.05 $458,613
2026-04-01 KLEIN JOSEPH S III Director — 22,321 $75.50 $1,686,302
2026-04-01 KLEIN JOSEPH S III Director — 22,321 $38.06 $880,707
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
943.71
+33.83%
705.14
-10.48%
787.65
+34.10%
587.37
Operating Revenue
943.71
+33.83%
705.14
-10.48%
787.65
+34.10%
587.37
Cost Of Revenue
15.91
+41.85%
11.21
+22.80%
9.13
-35.30%
14.12
Reconciled Cost Of Revenue
15.91
+41.85%
11.21
+22.80%
9.13
-35.30%
14.12
Gross Profit
927.80
+33.70%
693.92
-10.87%
778.51
+35.81%
573.25
Operating Expense
1,309.52
+12.02%
1,169.03
+3.25%
1,132.24
+15.13%
983.44
Research And Development
915.62
+1.56%
901.53
+0.21%
899.62
+7.98%
833.15
Selling General And Administration
393.90
+47.25%
267.50
+14.99%
232.62
+54.77%
150.29
General And Administrative Expense
393.90
+47.25%
267.50
+15.00%
232.60
+54.76%
150.30
Salaries And Wages
41.90
+13.24%
37.00
+34.55%
27.50
+6.18%
25.90
Other Gand A
352.00
+52.71%
230.50
+12.38%
205.10
+64.87%
124.40
Total Expenses
1,325.43
+12.30%
1,180.24
+3.41%
1,141.38
+14.42%
997.56
Operating Income
-381.72
+19.66%
-475.11
-34.31%
-353.73
+13.76%
-410.19
Total Operating Income As Reported
-381.68
+19.66%
-475.08
-34.31%
-353.73
+13.76%
-410.19
EBITDA
-273.12
+22.79%
-353.72
-53.79%
-230.01
-0.99%
-227.76
Normalized EBITDA
-381.11
+16.76%
-457.85
-44.37%
-317.14
+19.79%
-395.36
Reconciled Depreciation
22.69
+3.20%
21.99
-2.26%
22.50
+1.78%
22.11
EBIT
-295.82
+21.26%
-375.71
-48.79%
-252.51
-1.06%
-249.86
Total Unusual Items
107.98
+3.70%
104.13
+19.52%
87.13
-48.02%
167.60
Total Unusual Items Excluding Goodwill
107.98
+3.70%
104.13
+19.52%
87.13
-48.02%
167.60
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Restructuring And Mergern Acquisition
—
—
—
0.00
Net Income
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Pretax Income
-379.60
+17.49%
-460.07
-37.76%
-333.96
-29.45%
-257.99
Net Non Operating Interest Income Expense
-90.08
+0.41%
-90.46
-11.05%
-81.46
-902.92%
-8.12
Interest Expense Non Operating
83.78
-0.68%
84.36
+3.56%
81.46
+902.92%
8.12
Net Interest Income
-90.08
+0.41%
-90.46
-11.05%
-81.46
-902.92%
-8.12
Interest Expense
83.78
-0.68%
84.36
+3.56%
81.46
+902.92%
8.12
Other Income Expense
92.13
-12.65%
105.46
+4.19%
101.22
-36.87%
160.33
Other Non Operating Income Expenses
-15.86
-1291.44%
1.33
-90.56%
14.10
+293.77%
-7.27
Gain On Sale Of Security
107.98
+3.70%
104.13
+19.52%
87.13
-48.02%
167.60
Tax Provision
1.79
+128.94%
-6.17
-119.09%
32.32
+175.38%
11.74
Tax Rate For Calcs
0.00
+1515.38%
0.00
-93.81%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
22.68
+1575.14%
1.35
-92.60%
18.30
-48.02%
35.20
Net Income Including Noncontrolling Interests
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Net Income From Continuing Operation Net Minority Interest
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Net Income From Continuing And Discontinued Operation
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Net Income Continuous Operations
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Minority Interests
—
—
—
0.00
Normalized Income
-466.70
+16.16%
-556.68
-27.94%
-435.12
-8.20%
-402.13
Net Income Common Stockholders
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Diluted EPS
-2.38
+21.71%
-3.04
-18.75%
-2.56
-34.74%
-1.90
Basic EPS
-2.38
+21.71%
-3.04
-18.75%
-2.56
-34.74%
-1.90
Basic Average Shares
160.01
+6.67%
150.00
+4.90%
143.00
+0.70%
142.00
Diluted Average Shares
160.01
+6.67%
150.00
+4.90%
143.00
+0.70%
142.00
Diluted NI Availto Com Stockholders
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Total Other Finance Cost
6.30
+3.28%
6.10
+3.39%
5.90
+11.32%
5.30
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
3,523.84
+17.32%
3,003.68
+0.45%
2,990.07
+18.00%
2,533.88
Current Assets
2,990.64
+14.13%
2,620.29
-0.82%
2,641.85
+19.94%
2,202.69
Cash Cash Equivalents And Short Term Investments
2,677.44
+16.53%
2,297.66
-1.44%
2,331.20
+17.33%
1,986.87
Cash And Cash Equivalents
372.26
+53.78%
242.08
-39.37%
399.27
+44.41%
276.47
Other Short Term Investments
2,305.18
+12.14%
2,055.58
+6.40%
1,931.93
+12.95%
1,710.40
Receivables
66.06
-28.34%
92.19
-5.72%
97.78
+282.87%
25.54
Other Receivables
66.06
-28.34%
92.19
-5.72%
97.78
+282.87%
25.54
Inventory
10.05
-19.69%
12.51
+68.15%
7.44
-66.23%
22.03
Raw Materials
1.04
-81.30%
5.56
+207.02%
1.81
-90.84%
19.76
Work In Process
7.91
+18.48%
6.68
+21.95%
5.48
+159.70%
2.11
Finished Goods
1.10
+297.10%
0.28
+79.22%
0.15
-6.10%
0.16
Other Current Assets
237.09
+8.79%
217.93
+6.09%
205.43
+22.10%
168.25
Total Non Current Assets
533.20
+39.08%
383.38
+10.10%
348.22
+5.14%
331.18
Net PPE
361.60
+41.19%
256.11
+5.42%
242.94
-5.04%
255.84
Gross PPE
470.68
+29.87%
362.42
+6.69%
339.70
-1.12%
343.55
Accumulated Depreciation
-109.08
-2.60%
-106.32
-9.88%
-96.76
-10.31%
-87.72
Properties
0.00
0.00
0.00
0.00
Land And Improvements
0.00
-100.00%
8.57
+0.00%
8.57
+0.00%
8.57
Buildings And Improvements
41.80
+1.39%
41.23
+0.00%
41.23
+0.17%
41.16
Machinery Furniture Equipment
101.17
+4.96%
96.39
+7.43%
89.73
+6.91%
83.93
Other Properties
238.55
+47.38%
161.86
-5.84%
171.90
-5.31%
181.54
Leases
89.15
+63.96%
54.38
+92.30%
28.28
-0.29%
28.36
Goodwill And Other Intangible Assets
—
—
—
—
Other Intangible Assets
—
—
—
—
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
171.60
+34.83%
127.28
+20.89%
105.28
+39.73%
75.34
Total Liabilities Net Minority Interest
3,034.75
+25.65%
2,415.32
-7.22%
2,603.39
+32.76%
1,960.99
Current Liabilities
781.57
+152.67%
309.32
-30.97%
448.09
+43.82%
311.56
Payables And Accrued Expenses
136.88
-9.61%
151.44
-13.99%
176.07
+7.18%
164.27
Payables
30.80
-28.38%
43.00
+52.59%
28.18
+16.58%
24.17
Accounts Payable
28.08
-34.64%
42.96
+65.07%
26.03
+45.23%
17.92
Current Accrued Expenses
106.09
-2.17%
108.44
-26.68%
147.89
+5.56%
140.10
Pensionand Other Post Retirement Benefit Plans Current
116.24
+66.97%
69.61
+2.79%
67.73
+37.72%
49.18
Total Tax Payable
2.71
+7879.41%
0.03
-98.42%
2.15
-65.58%
6.25
Income Tax Payable
2.71
+7879.41%
0.03
-98.42%
2.15
-65.58%
6.25
Current Debt And Capital Lease Obligation
454.69
+4800.16%
9.28
-82.55%
53.16
+605.55%
7.54
Current Debt
454.69
+4800.16%
9.28
-82.55%
53.16
+605.55%
7.54
Other Current Borrowings
454.69
+4800.16%
9.28
-82.55%
53.16
+605.55%
7.54
Current Deferred Liabilities
73.76
-6.62%
78.99
-47.73%
151.13
+66.85%
90.58
Current Deferred Revenue
73.76
-6.62%
78.99
-47.73%
151.13
+66.85%
90.58
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
2,253.18
+6.99%
2,106.01
-2.29%
2,155.30
+30.67%
1,649.43
Long Term Debt And Capital Lease Obligation
1,609.83
+14.39%
1,407.29
+0.49%
1,400.38
+2.84%
1,361.66
Long Term Debt
1,347.44
+8.19%
1,245.48
+1.30%
1,229.50
+3.96%
1,182.72
Long Term Capital Lease Obligation
262.38
+62.16%
161.81
-5.31%
170.88
-4.51%
178.94
Non Current Deferred Liabilities
92.00
-41.21%
156.50
-35.11%
241.18
-16.19%
287.77
Non Current Deferred Revenue
92.00
-41.21%
156.50
-35.11%
241.18
-16.19%
287.77
Other Non Current Liabilities
551.35
+1.69%
542.21
+5.54%
513.74
—
Stockholders Equity
489.09
-16.87%
588.35
+52.15%
386.69
-32.50%
572.89
Common Stock Equity
489.09
-16.87%
588.35
+52.15%
386.69
-32.50%
572.89
Capital Stock
0.16
+3.16%
0.16
+9.72%
0.14
+1.41%
0.14
Common Stock
0.16
+3.16%
0.16
+9.72%
0.14
+1.41%
0.14
Share Issued
163.30
+3.42%
157.91
+9.40%
144.34
+1.61%
142.06
Ordinary Shares Number
163.30
+3.42%
157.91
+9.40%
144.34
+1.61%
142.06
Additional Paid In Capital
3,145.40
+9.64%
2,868.81
+29.51%
2,215.10
+7.54%
2,059.85
Retained Earnings
-2,631.20
-16.95%
-2,249.81
-25.27%
-1,795.91
-25.62%
-1,429.62
Gains Losses Not Affecting Retained Earnings
-25.28
+17.95%
-30.81
+5.62%
-32.65
+43.21%
-57.48
Other Equity Adjustments
-25.28
+17.95%
-30.81
+5.62%
-32.65
+43.21%
-57.48
Total Equity Gross Minority Interest
489.09
-16.87%
588.35
+52.15%
386.69
-32.50%
572.89
Total Capitalization
1,836.53
+0.15%
1,833.84
+13.47%
1,616.19
-7.94%
1,755.61
Working Capital
2,209.07
-4.41%
2,310.97
+5.34%
2,193.76
+16.00%
1,891.13
Invested Capital
2,291.22
+24.31%
1,843.12
+10.41%
1,669.35
-5.32%
1,763.14
Total Debt
2,064.51
+45.74%
1,416.57
-2.54%
1,453.54
+6.16%
1,369.19
Net Debt
1,429.87
+41.20%
1,012.69
+14.64%
883.40
-3.33%
913.78
Capital Lease Obligations
262.38
+62.16%
161.81
-5.31%
170.88
-4.51%
178.94
Net Tangible Assets
489.09
-16.87%
588.35
+52.15%
386.69
-32.50%
572.89
Tangible Book Value
489.09
-16.87%
588.35
+52.15%
386.69
-32.50%
572.89
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-268.58
+46.38%
-500.95
-62.90%
-307.51
-12.08%
-274.37
Cash Flow From Continuing Operating Activities
-268.58
+46.38%
-500.95
-62.90%
-307.51
-12.08%
-274.37
Net Income From Continuing Operations
-381.39
+15.97%
-453.90
-23.92%
-366.29
-35.80%
-269.72
Depreciation Amortization Depletion
22.69
+3.20%
21.99
-2.26%
22.50
+1.78%
22.11
Depreciation
20.25
+3.06%
19.65
-1.43%
19.94
+1.26%
19.69
Amortization Cash Flow
2.44
+4.41%
2.34
-8.71%
2.56
+5.96%
2.42
Depreciation And Amortization
22.69
+3.20%
21.99
-2.26%
22.50
+1.78%
22.11
Amortization Of Intangibles
2.44
+4.41%
2.34
-8.71%
2.56
+5.96%
2.42
Other Non Cash Items
27.13
-21.50%
34.55
+15.41%
29.94
+457.23%
5.37
Stock Based Compensation
133.87
+2.82%
130.20
+23.05%
105.81
+5.53%
100.26
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
4.06
-69.55%
13.33
+99.79%
6.67
+104.53%
-147.35
Gain Loss On Investment Securities
-9.28
-420.89%
2.89
+82.00%
1.59
+101.06%
-149.91
Gain Loss On Sale Of PPE
-3.99
-153.90%
7.40
-55.53%
16.65
+3035.40%
0.53
Change In Working Capital
-51.22
+75.54%
-209.39
-171.02%
-77.26
-1120.47%
7.57
Change In Receivables
26.13
+367.42%
5.59
+107.76%
-72.06
-298.19%
36.36
Change In Inventory
-13.67
-169.65%
-5.07
-105.39%
-2.47
-146.36%
5.33
Change In Payables And Accrued Expense
36.59
+245.70%
-25.12
-218.68%
21.16
-63.61%
58.16
Change In Accrued Expense
51.95
+226.39%
-41.11
-415.16%
13.04
-77.14%
57.06
Change In Payable
-15.36
-196.06%
15.99
+96.95%
8.12
+642.14%
1.09
Change In Account Payable
-15.36
-196.06%
15.99
+96.95%
8.12
+642.14%
1.09
Change In Other Working Capital
-67.05
+57.81%
-158.94
-1710.46%
9.87
+115.17%
-65.03
Change In Other Current Assets
-33.21
-28.44%
-25.86
+23.42%
-33.76
-23.97%
-27.23
Investing Cash Flow
-277.78
-107.25%
-134.03
+37.41%
-214.13
+18.47%
-262.64
Cash Flow From Continuing Investing Activities
-277.78
-107.25%
-134.03
+37.41%
-214.13
+18.47%
-262.64
Net PPE Purchase And Sale
-51.44
-13.61%
-45.28
-90.21%
-23.80
-51.42%
-15.72
Purchase Of PPE
-51.44
-13.61%
-45.28
-90.21%
-23.80
-51.42%
-15.72
Capital Expenditure
-57.08
-13.39%
-50.34
-79.86%
-27.99
-39.26%
-20.10
Net Investment Purchase And Sale
-220.69
-163.71%
-83.69
+55.04%
-186.14
+62.52%
-496.62
Purchase Of Investment
-1,918.56
-3.55%
-1,852.86
-4.63%
-1,770.81
-19.18%
-1,485.77
Sale Of Investment
1,697.87
-4.03%
1,769.17
+11.64%
1,584.68
+60.21%
989.15
Net Intangibles Purchase And Sale
-5.64
-11.44%
-5.06
-20.96%
-4.18
+4.43%
-4.38
Purchase Of Intangibles
-5.64
-11.44%
-5.06
-20.96%
-4.18
+4.43%
-4.38
Net Other Investing Changes
—
—
0.02
-99.99%
254.08
Financing Cash Flow
675.84
+41.37%
478.06
-25.78%
644.08
+1264.81%
-55.30
Cash Flow From Continuing Financing Activities
675.84
+41.37%
478.06
-25.78%
644.08
+1264.81%
-55.30
Net Issuance Payments Of Debt
502.19
+1224.19%
-44.67
-151.41%
86.90
+271.44%
-50.69
Issuance Of Debt
770.00
0.00
-100.00%
575.00
0.00
Repayment Of Debt
-267.81
-499.53%
-44.67
+90.85%
-488.10
-862.99%
-50.69
Long Term Debt Issuance
770.00
0.00
-100.00%
575.00
0.00
Long Term Debt Payments
-267.81
-160268.26%
-0.17
-4.38%
-0.16
+99.68%
-50.69
Net Long Term Debt Issuance
502.19
+300809.58%
-0.17
-100.03%
574.84
+1234.12%
-50.69
Short Term Debt Payments
0.00
+100.00%
-44.50
+90.88%
-487.94
0.00
Net Short Term Debt Issuance
0.00
+100.00%
-44.50
+90.88%
-487.94
0.00
Net Common Stock Issuance
192.60
-63.15%
522.73
+957.26%
49.44
+675.80%
6.37
Common Stock Payments
—
—
—
0.00
Repurchase Of Capital Stock
—
—
—
0.00
Proceeds From Stock Option Exercised
—
—
0.00
0.00
Net Other Financing Charges
-18.95
—
507.74
+4723.41%
-10.98
Changes In Cash
129.48
+182.52%
-156.92
-228.16%
122.44
+120.67%
-592.30
Effect Of Exchange Rate Changes
0.70
+357.14%
-0.27
-177.56%
0.35
+184.21%
-0.42
Beginning Cash Position
242.08
-39.37%
399.27
+44.41%
276.47
-68.19%
869.19
End Cash Position
372.26
+53.78%
242.08
-39.37%
399.27
+44.41%
276.47
Free Cash Flow
-325.67
+40.93%
-551.29
-64.32%
-335.50
-13.93%
-294.47
Interest Paid Supplemental Data
10.78
-0.80%
10.87
+66.91%
6.51
+124.71%
2.90
Income Tax Paid Supplemental Data
—
—
48.33
+864.75%
5.01
Amortization Of Securities
-23.73
+37.10%
-37.73
-30.63%
-28.89
-490.92%
7.39
Common Stock Issuance
192.60
-63.15%
522.73
+957.26%
49.44
+675.80%
6.37
Issuance Of Capital Stock
192.60
-63.15%
522.73
+957.26%
49.44
+675.80%
6.37
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category